Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 12/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12878807 | 0.92 | EPHX1 (0.39) | EPHX1ZDHHC20ZDHHC2SMN1; SMN2 | |
| SCHEMBL24063869 | 0.85 | CASP2 (0.38) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 | |
| SCHEMBL19057654 | 0.83 | EPHX1 (0.50) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 | |
| SCHEMBL25697792 | 0.83 | EPHX1 (0.50) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 | |
| SCHEMBL22861925 | 0.83 | EPHX1 (0.50) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 | |
| SCHEMBL25881306 | 0.83 | EPHX1 (0.50) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 | |
| SCHEMBL20322090 | 0.81 | EPHX1 (0.47) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 | |
| SCHEMBL23451102 | 0.80 | ALDH1A1 (0.41) | SMN1; SMN2 | |
| SCHEMBL23568035 | 0.80 | MEN1 (0.43) | — | |
| SCHEMBL22079816 | 0.80 | EPHX1 (0.47) | EPHX1ZDHHC20ZDHHC2CASP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | EPHX1 1751/4885ZDHHC20 1271/4885ZDHHC2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.